View Item 

Show simple item record

The physician's role in selecting a factor replacement therapy
dc.contributor.authorPipe, Steven W.en_US
dc.date.accessioned2010-06-01T19:40:55Z
dc.date.available2010-06-01T19:40:55Z
dc.date.issued2006-03en_US
dc.identifier.citationPIPE, S. W. (2006). "The physician's role in selecting a factor replacement therapy." Haemophilia 12(s1): 21-25. <http://hdl.handle.net/2027.42/72816>en_US
dc.identifier.issn1351-8216en_US
dc.identifier.issn1365-2516en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/72816
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16445814&dopt=citationen_US
dc.format.extent58635 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights2006 Blackwell Publishing Ltden_US
dc.subject.otherHaemophiliaen_US
dc.subject.otherPathogensen_US
dc.subject.otherPlasmaen_US
dc.subject.otherRecombinanten_US
dc.subject.otherTherapyen_US
dc.titleThe physician's role in selecting a factor replacement therapyen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid16445814en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/72816/1/j.1365-2516.2006.01197.x.pdf
dc.identifier.doi10.1111/j.1365-2516.2006.01197.xen_US
dc.identifier.sourceHaemophiliaen_US
dc.identifier.citedreferenceLeveton LB, Sox HC Jr, Stoto MA, eds. HIV and the Blood Supply: an Analysis for Crisis Decisionmaking. Washington, DC: National Academy Press, 1995; 1 – 17.en_US
dc.identifier.citedreferenceStoto MA. The precautionary principle and emerging biological risks: lessons from swine flu and HIV in blood products. Public Health Rep 2002; 117: 546 – 52.en_US
dc.identifier.citedreference 3  National Hemophilia Foundation. MASAC recommendations Concerning the Treatment of Hemophilia and Other Bleeding Disorders. MASAC Document no. 151, November 2003. Published online at http://www.hemophilia.org/research/masac/masac151.pdf. Accessed July 2004.en_US
dc.identifier.citedreferenceChandra S, Groener A, Feldman F. Effectiveness of alternative treatments for reducing potential viral contaminants from plasma-derived products. Thromb Res 2002; 105: 391 – 400.en_US
dc.identifier.citedreferenceHoots WK. History of plasma-product safety. Transfus Med Rev 2001; 15 ( Suppl. 1 ): 3 – 10.en_US
dc.identifier.citedreferenceFischer G, Hoots WK, Abrams C. Viral reduction techniques: types and purpose. Transfus Med Rev 2001; 15 ( 2 Suppl. 1 ): 27 – 39.en_US
dc.identifier.citedreference 7  Centers for Disease Control and Prevention. CDC's Universal Data Collection project: blood safety. February 2002. Published online at http://www.cdc.gov/ncbddd/hbd/blood_safety_facts.htm. Accessed March 2005.en_US
dc.identifier.citedreference 8  Centers for Disease Control and Prevention, National Center for Infectious Diseases. 2005 West Nile virus viremic blood donor activity in the United States. Reported to the CDC as of November 15, 2005. Available at http://www.cdc.gov/ncidod/dvbid/westnile/surv&control05Maps_Viremic.htm. Accessed November 2005.en_US
dc.identifier.citedreferenceMiekka SI, Busby TF, Reid B, Pollock R, Ralston A, Drohan WN. New methods for inactivation of lipid-enveloped and non-enveloped viruses. Haemophilia 1998; 4: 402 – 8.en_US
dc.identifier.citedreferenceYokoyama T, Murai K, Murozuka T, Wakisaka A, Tanifuji M, Fujii N et al. Removal of small non-enveloped viruses by nanofiltration. Vox Sang 2004; 86: 225 – 9.en_US
dc.identifier.citedreferenceSantagostino E, Mannucci PM, Gringeri A et al. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization. Transfusion 1997; 37: 517 – 22.en_US
dc.identifier.citedreferenceSoucie JM, Siwak EB, Hooper WC, Evatt BL, Hollinger FB and the Universal Data Collection Project Working Group. Human parvovirus B19 in young male patients with hemophilia A: associations with treatment product exposure and joint range-of-motion limitation. Transfusion 2004; 44: 1179 – 85.en_US
dc.identifier.citedreferenceBrown SA. Issues in making a therapeutic choice: recombinant and/or human-derived products. Haemophilia 2000; 6: 12 – 9.en_US
dc.identifier.citedreferenceAledort LM. Making a therapeutic choice: human versus recombinant fractions – can we do it ? Haemophilia 2001; 7 ( Suppl. 1 ): 1 – 3.en_US
dc.identifier.citedreferenceSoucie JM, Richardson LC, Evatt BL et al. Risk factors for infection with HBV and HCV in a large cohort of hemophiliac males. Transfusion 2001; 41: 338 – 43.en_US
dc.identifier.citedreferenceChambost H, Ljung R. Changing pattern of care of boys with haemophilia in western European centres. Haemophilia 2005; 11: 92 – 9.en_US
dc.identifier.citedreferenceGiangrande P., Haemophilia B. Christmas disease. Expert Opin Pharmacother 2005; 6: 1517 – 24.en_US
dc.identifier.citedreferenceGiles AR, Rivard GE, Teitel J, Walker I. Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. Transfus Sci 1998; 19: 139 – 48.en_US
dc.identifier.citedreference19  Association of Hemophilia Clinic Directors of Canada. Clinical practice guidelines: Hemophilia and von Willebrand's disease: 2. Management (Edition 2, Update 2). July 7, 1999. Published online at http://www.ahcdc.ca/vWDManagement.html. Accessed April 2005.en_US
dc.identifier.citedreference20  United Kingdom Haemophilia Centre Doctors’ Organisation on behalf of The Department of Health Forward Planning and Monitoring Group. Rollout of Recombinant Products for all Adult Haemophilia Patients in England: Report of 2003/2004. September 2004. Published online at http://www.dh.gov.uk/assetRoot/04/09/00/63/04090063.pdf. Accessed September 2005.en_US
dc.identifier.citedreferenceFarrugia A. Evolving perspectives in product safety for haemophilia. Haemophilia 2002; 8: 236 – 43.en_US
dc.identifier.citedreferenceMauser-Bunschoten EP, Roosendaal G, van den Berg HM. Product choice and haemophilia treatment in the Netherlands. Haemophilia 2001; 7: 8.en_US
dc.identifier.citedreferenceMantovani LG, Monzini MS, Mannucci PM, Scalone L, Villa M, Gringeri A. Differences between patients’, physicians’ and pharmacists’ preferences for treatment products in haemophilia: a discrete choice experiment. Haemophilia 2005; 11: 589 – 97.en_US
dc.identifier.citedreferenceMiller R. The responsibility of separating truth from myth to patient and family. Haemophilia 2001; 7: 91 – 5.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2516.2006.01197.x.pdf
Size:
57.26KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.